Travere Therapeutics

Prescription pharmaceutical manufacturer of medications.

Based in CA

🤖

AI Overview

With $1.8M in lobbying spend across 30 quarterly filings, Travere Therapeutics is a significant lobbying presence. They deploy 14 individual lobbyists

$1.8M

Total Lobbying Spend

Quarterly Filings

Lobbying Firms Used

Individual Lobbyists

Spending by Year

Year	Lobbying Spend
2018	$200K
2019	$240K
2020	$180K
2021	$230K
2022	$240K
2023	$240K
2024	$240K
2025	$270K

Lobbying Firms

ALSTON & BIRD LLP

What They Lobby For

Issues related to Section 53116 of Pub. L. 115-123 concerning Medicare Part D coverage gap; issues related to FY 2019 budget proposals with respect to Medicare and Medicaid reform provisions.
Medical research, NIH funding, and related appropriations issues.
Issues related to Tax Cuts and Jobs Act's provisions relating to Orphan Drug Tax Credit, development, and rare disease patient issues.
Intellectual property issues and commercial litigation.
Rare disease patient care and screening and coverage issues in authorization and appropriations legislation including Omnibus Appropriations Act of 2018.
Issues related to Orphan Drug Act, Drug Quality and Security Act, drug pricing, Prescription Drug User Fee Act implementations; H.R. 2051, Fast Generics Act; S.3056, CREATES Act; FDA issues.
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Rare disease patient care and screening and coverage issues in authorization and appropriations legislation; S. 1151 Credit for Caring Act.
Issues related to FY 2019 budget proposals with respect to Medicare and Medicaid reform provisions.
Issues related to Orphan Drug Act, Drug Quality and Security Act, drug pricing, Opioid legislation; H.R. 2051, Fast Generics Act; S. 974, CREATES Act; FDA issues.